In Swedish

Technical advances offer new potential to TK1 as a tumor biomarker

A recently published review paper highlights TK1 as a tumor biomarker

Among other advantages the authors summarize that

  • the immunoassay of TK1 makes it a more sensitive biomarker for studying solid malignancies, thereby increasing its value as a biomarker
  • TK1 levels in malignancies are associated with clinical stage, offering potential for patient and subject stratification
  • Elevated and/or increasing serum TK1 levels after treatment indicate therapy escape


Authors are Kiran Kumar Jagarlamudi and Martin Shaw.

 

Read more here

Alertix Canine

Assay for early detection, monitoring and screening of tumor diseases in dogs. The assay is available to veterinary clinics and laboratories in Sweden and Scandinavia.
Read more about Alertix Canine

Alertix Feline

Assay for early detection, monitoring and screening of tumor diseases in cats. The assay is under development.
Read more about Alertix Feline
Under utveckling

Alertix Equine

Assay for early detection, monitoring and screening of tumor diseases in horses. The assay is under development.
Under utveckling
Read more about Alertix Equine

About cancer in companion animals

Did you know that our companion animals are afflicted by cancer as often as humans? Dogs and cats share not only our living environment but also our lifestyle. Because of this they are exposed to the same risk factors for cancer. Veterinary care is getting better and better at treating cancer in companion animals. But the crucial factor of success is that the disease is detected in time.

Read more about cancer in companion animals